The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 03, 2023

Filed:

Nov. 09, 2021
Applicants:

Peptron, Inc., Daejeon, KR;

The United States, As Represented BY the Secretary, Department of Health and Human Services, Rockville, MD (US);

Inventors:

Dong Seok Kim, Columbia, MD (US);

Hee Kyung Kim, Daejeon, KR;

Nigel H. Greig, Phoenix, MD (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/50 (2006.01); A61P 25/28 (2006.01); A61P 25/30 (2006.01); A61P 25/16 (2006.01); A61K 9/00 (2006.01); A61K 9/48 (2006.01); A61K 38/26 (2006.01); A61M 5/142 (2006.01);
U.S. Cl.
CPC ...
A61K 9/5031 (2013.01); A61K 9/0019 (2013.01); A61K 9/4866 (2013.01); A61K 38/26 (2013.01); A61M 5/14228 (2013.01); A61P 25/16 (2018.01); A61P 25/28 (2018.01); A61P 25/30 (2018.01);
Abstract

The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject. The method includes administering to the systemic blood circulation of the subject a therapeutically effective amount of a neuroprotective polypeptide by a controlled-release formulation or a device providing a sustained release of the neuroprotective polypeptide including at least one neuroprotective polypeptide selected from the group consisting of GLP-1, exendin-4, or a therapeutically effective GLP-1 or exendin-4 analogue; the neuroprotective polypeptide binds to and activates a receptor that binds at least one of GLP-1, exendin-4, or a combination thereof; and the controlled-release neuroprotective formulation or the sustained release of the neuroprotective polypeptide enhances the delivery of the neuroprotective polypeptide across a blood-brain barrier (BBB) of the subject to at least a portion of the CNS relative to a rapid release formulation of the neuroprotective polypeptide. Also disclosed is a method of treating a subject with a CNS-related disease or reducing at least one symptom of a CNS-related disease in a subject in need thereof.


Find Patent Forward Citations

Loading…